Amgen And Avalere Reports Reveal "Upside Down" Payer Biosimilar Realities

Last week was an important one for the biosimilar industry, thanks to the publication of two reports and the highly anticipated speech from President Trump on drug pricing. While many articles have been written about what may and may not come from the president’s plans, much less attention has been devoted to the two reports.